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Abstract
During sepsis, liver dysfunction is common, and failure of mitochondria to effectively couple oxygen consumption with
energy production has been described. In addition to sepsis, pharmacological agents used to treat septic patients may
contribute to mitochondrial dysfunction. This study addressed the hypothesis that remifentanil interacts with hepatic
mitochondrial oxygen consumption. The human hepatoma cell line HepG2 and their isolated mitochondria were exposed to
remifentanil, with or without further exposure to tumor necrosis factor-a (TNF-a). Mitochondrial oxygen consumption was
measured by high-resolution respirometry, Caspase-3 protein levels by Western blotting, and cytokine levels by ELISA.
Inhibitory kBa (IkBa) phosphorylation, measurement of the cellular ATP content and mitochondrial membrane potential in
intact cells were analysed using commercial ELISA kits. Maximal cellular respiration increased after one hour of incubation
with remifentanil, and phosphorylation of IkBa occurred, denoting stimulation of nuclear factor kB (NF-kB). The effect on
cellular respiration was not present at 2, 4, 8 or 16 hours of incubation. Remifentanil increased the isolated mitochondrial
respiratory control ratio of complex-I-dependent respiration without interfering with maximal respiration. Preincubation
with the opioid receptor antagonist naloxone prevented a remifentanil-induced increase in cellular respiration. Remifentanil
at 106 higher concentrations than therapeutic reduced mitochondrial membrane potential and ATP content without
uncoupling oxygen consumption and basal respiration levels. TNF-a exposure reduced respiration of complex-I, -II and -IV,
an effect which was prevented by prior remifentanil incubation. Furthermore, prior remifentanil incubation prevented TNF-
a-induced IL-6 release of HepG2 cells, and attenuated fragmentation of pro-caspase-3 into cleaved active caspase 3 (an early
marker of apoptosis). Our data suggest that remifentanil increases cellular respiration of human hepatocytes and prevents
TNF-a-induced mitochondrial dysfunction. The results were not explained by uncoupling of mitochondrial respiration.
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Introduction
Severe sepsis and septic shock are major causes of death in
intensive care patients [1,2]. The causes of organ dysfunction and
failure are unclear, but inadequate tissue perfusion, systemic
inflammation, and direct metabolic changes at the cellular level
are all likely to contribute [3–5]. The liver is a central organ in
homeostasis, with vital metabolic and immunological functions.
During sepsis, liver dysfunction is common, and contributes to the
high mortality observed in these patients [6–8]. Nevertheless, the
precise mechanisms by which the liver is affected are unclear [9–
10]. Failure of mitochondria to effectively couple oxygen
consumption with energy production has been described in sepsis
[11]. The pathogenesis of mitochondrial dysfunction is multifac-
torial, but nitric oxide (NO) [12–14], reactive oxygen species
(ROS) overproduction [11], anti-oxidant deficiency [11–14] and
an increase in inner mitochondrial membrane permeability [15–
16] are likely to contribute. In addition to sepsis, pharmacological
agents used to treat septic patients may contribute to mitochon-
drial dysfunction [17].
The commonly used sedative drug propofol decreases oxygen
consumption in brain synaptosomes [18] and impairs mitochon-
drial respiration in isolated perfused guinea pig hearts [19].
Hanley et al. showed that halothane, isoflurane and sevoflurane
inhibit NADH:ubiquinone oxidoreductase (complex I) of cardiac
mitochondria [20].
Remifentanil is used to provide analgesia and sedation in
critically ill patients [21]. Remifentanil is a synthetic short-acting
opioid analgesic drug and is a specific m-opioid receptor agonist
[22]. The potent m-opioid activity of remifentanil is antagonised by
narcotic antagonists, such as naloxone. Unlike other synthetic
opioids which are metabolised in the liver, remifentanil has a short
half-life and does not accumulate in the body, but is rapidly
metabolised by non-specific blood and tissue esterases to
carboxylic acid metabolite, which has 1/4600th the potency of
the remifentanil [23,24].
The effect of remifentanil on hepatic mitochondrial bioener-
getics has not yet been studied. The primary objective of the
present study was to investigate whether remifentanil regulates
mitochondrial function in the cultured human hepatocellular
carcinoma cell line (HepG2). We used this cell line because it
retains most of the liver-specific proteins, metabolic enzymes and
functions of primary human hepatocytes [25]. As examples,
HepG2 cells and primary human hepatocytes behave similarly
when stimulated to express cytochrome P450 [26], genes involved
in RNA processing and mitochondrial function [27], and Phase II
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enzymes [28], with respect to nicotinic acid transport into cells
[29], and in terms of acute-phase protein production when
stimulated with interleukins [30]. Furthermore, HepG2 cells are
available in large quantities, which makes it possible to perform
multiple experiments evaluating biochemical functions of liver
cells.
Tumour necrosis factor-a (TNF-a) is one of the important
mediators of inflammation in sepsis, and may alter mitochondrial
function in human hepatocytes [31]. As a secondary objective, we
investigated whether remifentanil interferes with TNF-a-induced
mitochondrial dysfunction in cultured HepG2 cells.
Results
Cellular oxygen consumption after incubation with
remifentanil
Incubation of HepG2 cells with remifentanil (1 hour, 50 ng/ml;
n = 15) induced a significant increase in complex I-dependent
respiration (116654 in controls [incubated in cell culture medium
alone] vs. 130660 pmoles/[s*Million cells] in stimulated cells;
p = 0.04), but not complex II- and IV-dependent respiration
(Figure 1a). At 1 hour of remifentanil incubation at a concentra-
tion of 500 ng/ml (n = 15), a significant increase in respiration was
observed for both complex I-dependent respiration (143638 in
controls vs. 175643 pmoles/[s*Million cells] in stimulated cells;
p = 0.001) and complex II-dependent respiration (150624 in
controls vs. 174627 pmoles/[s*Million cells] in stimulated cells;
p,0.001) but not complex IV-dependent cellular respiration
(Figure 1f). After 2, 4, 8 and 16 hours of incubation with
remifentanil at 50 ng/ml (n = 15 each) and 1 hour at 5 ng/ml, no
significant changes in cellular respiration were observed for any of
the complexes (Figure 1b–e, 1g). Incubation of the cells with the
major component of the vehicle of remifentanil did not affect
cellular respiration (data not shown).
Cellular oxygen consumption after naloxone antagonism
In order to see if the alterations in mitochondrial respiration
could be prevented by the presence of an opioid receptor
antagonist, we determined the effect of the antagonist naloxone
(Figure 2). For these experiments, the cells were pre-incubated for
a 1-hour period with naloxone at a concentration of 1000 ng/ml
before the addition of remifentanil (50 or 500 ng/ml; n= 15,
Figure 2a, 2b). In another series, the effect of naloxone alone
(1000 ng/ml) for 2 hours was compared to medium alone (n= 10;
Figure 2C). The controls were incubated with medium alone.
Afterwards, cellular respiration was measured. The data indicate
that the effect of remifentanil is prevented with naloxone: cells pre-
treated with naloxone before the addition of remifentanil exhibited
no significant changes in complex activities in comparison with
controls. Naloxone alone did not affect mitochondrial respiration
(Figure 2c).
Remifentanil (50 or 500 ng/ml) induces phosphorylation
of IkBa
To assess the effect of remifentanil (50 or 500 ng/ml) on
intracellular signaling, we investigated the phosphorylation state of
IkBa. Phosphorylation of IkBa leads to its degradation and results
in the release and activation of transcription factor NF-kB.
Treatment with remifentanil for 30 min (50 or 500 ng/ml) led to
the increased chemiluminescence signal arising from phosphory-
lation of IkBa (remifentanil 50 ng/ml: 2.9 fold, p = 0.04 and
500 ng/ml: 1.8 fold, p = 0.007) (Figure 3).
HepG2 isolated mitochondrial oxygen consumption after
incubation with remifentanil
HepG2 cells’ isolated mitochondria were incubated with
remifentanil at 50 or 500 ng/ml (n = 5) for 1 hour (Figure 4).
There were no significant changes in maximal mitochondrial
respiration (state 3) for any of the complexes. However,
remifentanil at a concentration of 500 ng/ml induced an increase
in the respiratory control ratio (RCR) of complex-I-dependent
respiration (1.8960.6 in controls [medium alone] vs. 1.9960.62 in
stimulated cells; p = 0.028) (Figure 4c).
Cellular oxygen consumption after incubating the cells
with TNF-a and remifentanil
To determine whether remifentanil interferes with TNF-a-
induced mitochondrial dysfunction, cells were treated for 30 min
with medium alone or remifentanil (50 or 500 ng/ml), followed by
incubation with TNF-a at 10 ng/ml (200 U/ml) for an additional
hour (n = 8). Afterwards, cellular respiration was measured. Each
individual respiration experiment was performed in four chambers
of high-resolution oxygraphs in parallel, one as a control and the
others for the treated cells, and was recorded simultaneously for
paired comparisons of the slopes of the oxygen concentrations of
each individual experiment. At 1 hour of TNF-a incubation, a
significant reduction in respiration was observed for complex I-
dependent (105617 in controls vs. 86613 pmoles/[s*million cells]
in stimulated cells; p = 0.001), complex II-dependent (92619 in
controls vs. 83617 pmoles/[s*million cells] in stimulated cells;
p = 0.0037) and complex IV-dependent respiration (108630 in
controls vs. 81622 pmoles/[s*million cells] in stimulated cells;
p,0.001) (Figure 5). Preincubation of the cells with remifentnil at
50 ng or 500 ng for 30 min prevented TNF-a-induced decrease in
mitochondrial respiration.
Remifentanil attenuates TNF-a-induced activation of
caspase-3 apoptosis signaling
Cleavage of pro-caspase-3 into cleaved active caspase 3 serves as
an early marker of apoptosis. To determine whether remifentanil
attenuates TNF-a-induced activation of caspase-3 apoptosis
signaling in HepG2 cells, we examined processing/activation of
caspase-3 (Figure 6). For these experiments, cells were incubated
with TNF-a at 10 ng/ml (200 U/ml) for 24 hours, or pretreated
with 50 or 500 ng/ml of remifentil (for 1 hour), followed by
incubation with medium alone or TNF-a at 10 ng/ml (200 U/ml)
for an additional 24 hours. We used an antibody which can
recognize both the inactive precursor procaspase-3 (,36 kDa) and
the mature active enzyme of ,17 kDa following cleavage by
upstream caspases. Treatment of the cells with TNF-a induced a
reduction in procaspase-3 protein band intensity, with visible
cleaved active caspase 3 fragments (densitometric analysis of
cleaved caspase protein levels: 0.660.57 arbitrary units [AU] in
controls vs. 2.8461.62 AU in cells treated with TNF-a; p = 0.02)
(n = 5). Pretreatment with remifentanil at a concentration of
500 ng/ml, followed by incubation with TNF-a, attenuated TNF-
a-induced cleavage of caspase-3 (0.6760.34 AU in cells pretreated
with remifentanil [500 ng/ml] followed by incubation with TNF-a
vs. 2.8461.62 AU in cells treated with TNF-a; p = 0.02).
However, pretreatment with remifentanil at a concentration of
50 ng/ml, followed by incubation with TNF-a, did not affect
TNF-a-induced cleavage of caspase-3 (1.4460.57 AU in cells
pretreated with remifentanil [50 ng/ml] followed by incubation
with TNF-a 2.8461.62 AU in cells treated with TNF-a; p = 0.1).
Remifentanil and Cultured Human Hepatocytes
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Cytokine release
Supernatants of HepG2 cultures were measured for IL-6 and
IL-10 contents after 24 hours of incubation with various agonists/
antagonists (Figure 7). Treatment of HepG2 cells with TNF-a
induced an increase in Il-6 levels (61.7645.27 ng/ml in controls
vs. 108.7625.38 ng/ml in cells treated with TNF-a; p = 0.03).
Pretreatment with remifentanil at a concentration of 500 ng/ml,
followed by incubation with TNF-a, prevented TNF-a-induced
IL-6 release (57622.44 ng/ml in cells pretreated with remifentanil
[500 ng/ml] followed by incubation with TNF-a; vs.
108.7625.38 ng/ml in cells treated with TNF-a; p = 0.008).
However, pretreatment with remifentanil at a concentration of
50 ng/ml, followed by incubation with TNF-a, did not affect
TNF-a-induced IL-6 release (108.6615.2 ng/ml in cells pretreat-
ed with remifentanil [50 ng/ml] followed by incubation with
TNF-a; vs. 108.7625.38 ng/ml in cells treated with TNF-a;
p = 0.92).
IL-10 levels in the supernatants of HepG2 cells were
undetectable in controls or cells treated with TNF-a, remifentanil,
naloxone or combinations of remifentanil and naloxone/TNF-a
(data not shown).
Membrane potential, ATP content and coupled and
uncoupled cellular respiration
Treatment of the cells with remifentanil at 50 and 500 ng/ml
for 1 hour induced a reduction in mitochondrial membrane
potential (Dym depolarization), expressed as the reductions in JC-
1 590/530 nm fluorescence ratios (0.08360.016 in controls vs.
0.06960.011 in cells treated with remifentanil at 50 ng/ml
[p= 0.001] and 0.06860.01 in cells treated with remifentanil at
500 ng/ml [p,0.0001]). Valinomycin (1 mg/ml, 1 hour incuba-
tion), which was used as positive control, also dissipated the
mitochondrial electrochemical potential (0.06060.019 vs controls,
p = 0.002) (Figure 8).
To assess whether reduction in the mitochondrial membrane
potential (50 and 500 ng/ml) was accompanied by a reduction in
cellular ATP levels, we measured the ATP content of the cells after
treatment with remifentanil (50 or 500 ng/ml). Treatment with
remifentanil for 1 hour led to a reduction in cellular ATP content
only at 500 ng/ml (11.6361.04 pmole/mg cellular protein in
remifentanil 500 ng/ml treated cells vs. 14.6962.39 pmole/mg in
controls, p = 0.023) (Figure 9).
Remifentanil at 500 ng/ml increased complex I- and II-
dependent respiration of permeabilized cellular respiration (using
exogenous substrates), and decreased cellular ATP content and
membrane potential, indicating that at high dosage it might act as
a mitochondrial uncoupler. Therefore we performed additional
experiments investigating the overall endogenous respiration of
intact cells in the absence of exogenous substrates and ADP. For
these experiments, cell were treated with remifentanil (500 ng/ml,
1 hour incubation) and endogenous basal cellular respiration,
FCCP uncoupled and oligomycin-insensitive respiration rates were
measured. Treatment of the cells with remifentanil (500 ng/ml,
1 hour incubation) did not affect basal endogenous cellular
respiration of intact cells (58.5632.4 in controls vs. 54.9632.2
in cells treated with remifentanil [p = 0.35] Figure 10A). FCCP-
uncoupled maximal respiration rates (respiration in the presence of
FCCP) tended to decrease (180.4685.2 in controls vs. 161.0686.1
cells treated with remifentanil p = 0.064) (Figure 10C), indicating a
tendency in decreased respiratory capacity after treatment with
remifentanil. Oligomycin-insensitive respiration which represents
non-phosphorylating respiration (Figure 10B), Oligomycin-sensi-
tive respiration (ATP turnover; data not shown) and uncoupled
RCRs (uRCRs: the ratio between FCCP and oligomycin-
insensitive respiration rates; 6.062.1 in controls vs. 6.162.0 in
cells treated with remifentanil [p = 0.7]) were not affected
(Figure 10D).
Discussion
In the current study, we demonstrate that in cultured human
hepatocytes, remifentanil improves mitochondrial bioenergetics
and prevents TNF-a-induced reduction of mitochondrial respira-
tion.
Figure 1. Cellular oxygen consumption after incubation with remifentanil. HepG2 permeabilised cells’ oxygen consumption for complex I, II
and IV after 1 hour (a) and 2(b), 4(c), 8(d), and 16 hours (e) of incubation with remifentanil at 50 ng/ml (n = 15 each) or after 1 hour of incubation with
remifentanil at 500 ng/ml (f) or 5 ng/ml (g) (C: control, R: remifentanil). Controls were incubated with medium alone. Data represent mean6SD.
Statistical significance between samples using paired samples t test is indicated.
doi:10.1371/journal.pone.0045195.g001
Figure 2. Cellular oxygen consumption after naloxone antagonism. HepG2 permeabilised cells’ oxygen consumption for complex I, II and IV.
Cells were incubated for 1 hour with medium alone (controls, white bars) or preincubated with naloxone (1000 ng/ml) for 1 hour followed by
incubation with remifentanil at 50 ng/ml (Figure 2a) or 500 ng/ml (Figure 2b) for an additional hour (black bars) (n = 15). Figure 2c: Cells were
incubated for 2 hour with medium alone (white bars) or incubated with naloxone (1000 ng/ml) for 2 hour (black bars) (n = 10). (C: control, R:
remifentanil, N: naloxone). Data represent mean6SD. Statistical significance between samples using paired samples t test is indicated.
doi:10.1371/journal.pone.0045195.g002
Remifentanil and Cultured Human Hepatocytes
PLOS ONE | www.plosone.org 4 September 2012 | Volume 7 | Issue 9 | e45195
We selected three different concentrations of remifentanil. At a
clinical and therapeutic blood concentration of 50 ng/ml [22,32],
remifentanil increased complex-I-dependent mitochondrial respi-
ration. At 10 times higher than therapeutic concentration
(500 ng/ml), remifentanil increased complex I- and II-dependent
respiration, indicating that higher doses of this drug lead to greater
alterations in mitochondrial bioenergetics. At one tenth of
therapeutic concentration (5 ng/ml), remifentanil did not affect
mitochondrial respiration.
Early on (within the first hour of incubation) we observed
remifentanil-induced increases in maximal cellular respiration, an
effect which was not present at later time points. This can be
explained by the ultra-short pharmacokinetic profile of the drug
[22–24] and the fact that in the present study remifentanil was not
administered continuously to the cell culture flasks. Remifentanil
exhibits rapid metabolism by non-specific esterases in the tissues,
principally to a carboxylic acid derivative, remifentanil acid (RA).
In patients treated with remifentanil, this carboxylic acid
derivative is eliminated by the kidneys; however, in our
experiments it should have accumulated in cell culture flasks.
Therefore we extended the mitochondrial respiration experiments
to up to 16 hours to ensure that the accumulated carboxylic acid
derivative of remifentanil does not interfere with cellular
respiration. One limitation of our study was that we did not
measure concentration-time profiles of remifentanil and its
metabolized carboxylic acid derivative in the cell culture flasks.
Remifentanil incubation at a concentration of 500 ng/ml
induced a significant increase in maximal exogenous ADP-
stimulated respiration (state 3) of permeabilized cells, using excess
substrates suggesting altered mitochondrial bioenergetics. State 3
respirations represent oxidative phosphorylation capacity of the
pemeabilized cells (or isolated mitochondria) in the presence of
saturating ADP and excess substrates. Maximal oxygen consump-
tion in state 3 is a combination of coupled and uncoupled
respiration (due to physiological or pathological conditions). To
investigate whether the observed increase in maximal respiration
of HepG2 cells treated with remifentanil is the result of
mitochondrial respiration uncoupling, we performed additional
respiratory experiments in intact cells. For these experiments, we
measured intact cellular basal endogenous respiration. To evaluate
the respiratory electron transfer system capacity, non-coupled
respiration was induced experimentally by titration of FCCP to
obtain the maximum flux. We did not observe any difference in
basal (endogenous) respiration of cells treated with remifentanil at
500 ng/ml compared to controls. Basal respiration of the intact
cells in the absence of exogenous substrates or ADP mainly reflects
cellular ATP requirement to maintain a basal metabolic rate and
not respiratory capacity [33]. Basal respiration of intact cells does
not represent saturating ADP-stimulated state 3 respiration and is
substrate limited. We further measured FCCP-uncoupled respira-
tion, which is a measure of the mitochondrial electron transport
chain capacity and integrity. Remifentanil induced a tendency to
reduce the maximum electron transport chain capacity of intact
cells. However, the uncoupled respiratory control ratio (uRCR)
which is the ratio of the FCCP uncoupled maximal respiration to
oligomycin-insensitive respiration, reflecting respiratory reserve
capacity, was not affected. We did not observe any difference in
state 4 respiration of isolated HepG2 mitochondria treated with
remifentanil at 500 ng/ml compared to controls indicating
absence of uncoupling. The present data suggest that remifentanil
Figure 3. Remifentanil (50 or 500 ng/ml) induces phosphory-
lation of IkBa. IkBa phosphorylation state is measured in HepG2 cell
extract 30 min after stimulation with remifentanil (50 or 500 ng/ml) by
a transcription factor Elisa kit (n = 4) (C: control [medium alone], R50:
remifentanil 50 ng/ml, R500: remifentanil 500 ng/ml). Data represent
mean6SD. Statistical significance between samples using unpaired t
test is indicated.
doi:10.1371/journal.pone.0045195.g003
Figure 4. HepG2 isolated mitochondrial oxygen consumption after incubation with remifentanil. HepG2 cells’ isolated mitochondrial
oxygen consumption for complex I, II and IV after 1 hour of incubation with remifentanil at 50 and 500 ng/ml (n = 5 for 6a and b, and n=4 for 6c) (C:
control [respiration buffer alone], R50: remifentanil 50 ng/ml, R500: remifentanil 500 ng/ml). Data represent mean6SD. Statistical significance
between samples using paired sample t test is indicated (*p,0.05 vs. control).
doi:10.1371/journal.pone.0045195.g004
Remifentanil and Cultured Human Hepatocytes
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does not uncouple HepG2 cells mitochondrial respiration. A
theoretical alternative explanation for the measured effects of
remifentanil is activation of mitochondrial ATP-sensitive K+
(mtKATP) channel. Activation of mtKATP channel can play an
essential role in activation the respiratory chain [34–38]. It has
been proposed that opening the mtKATP channel can lead to
increased mitochondrial matrix volume, increased respiration and
induces a slight reduction in mitochondrial membrane potential
[39]. In isolated rat heart mitochondria, mtKATP channel
opening depolarized mitochondrial membrane potential, in-
creased respiration, slowed ATP production, and increased matrix
volume [40].
Since remifentanil is an opioid acting on m-type receptors [22]
and expression of the m-opioid receptor in hepatocytes has been
Figure 5. Cellular oxygen consumption after incubating the cells with TNF-a and remifentanil. HepG2 permeabilized cells’ oxygen
consumption for complex I, II and IV (state 3), incubated with medium alone (controls), TNF-a (10 ng/ml; 200 U/ml) for 1 hour, or preincubated with
50 ng/ml or 500 ng/ml remifentanil for 30 minutes followed by incubation with TNF-a (10 ng/ml, 200 U/ml) for an additional hour (n = 8). Each
individual respiration experiment was performed in four chambers of high-resolution oxygraphs in parallel, one as a control and the others for the
treated cells, and was recorded simultaneously for paired comparisons of the slopes of the oxygen concentrations of each individual experiment.
(R50: remifentanil 50 ng/ml, R500: remifentanil 500 ng/ml). Data represent mean6SD. Statistical significance between samples using paired t test is
indicated (*p,0.05 vs. control, **p,0.01 vs. control).
doi:10.1371/journal.pone.0045195.g005
Figure 6. Remifentanil attenuates TNF-a-induced activation of caspase-3 apoptosis signalling.Western blot analysis of procaspase-3 and
cleaved caspase 3 (panel a) from HepG2 cells after incubation with medium alone (controls), TNF-a (10 ng/ml) and remifentanil (50 and 500 ng/ml)
for 24 h or preincubation with remifentanil (50 and 500 ng/ml, 1 h incubation) followed by incubation with TNF-a (10 ng/ml) for an additional 24 h
(n = 5) (The polyclonal antibody used is specific to recognize both the precursor procaspase-3 ,36 kDa and the mature active enzymes of 17–20 kDa
following cleavage by upstream caspases) (C: control, R50: remifentanil 50 ng/ml, R500: remifentanil 500 ng/ml). Densitometric analysis of cleaved
caspase protein levels (panel b): the protein bands were analyzed and quantified densitometrically using Quantity One software from Bio-Rad. The
relative levels of cleaved caspase 3 expression were normalized to actin and the results are expressed as arbitrary units and are means+/2SD for five
independent experiments. Statistical analysis for cleaved caspase 3 levels was performed by one-way analysis of variance (ANOVA): # p= 0.002.
Afterwards, all groups were divided into subgroups and subsequent one-way ANOVA was performed in the subgroups (subgroup 1: control, TNF-a,
R50 and R500 (p = 0.006); subgroup 2: TNF-a, R50+TNF-a and R500+TNF-a; p,0.016) followed by an independent t-test in each subgroup.
* = independent t-test, TNF-a vs. control (p = 0.02). & = independent t-test R500+TNF- a vs. TNF-a (p = 0.02).
doi:10.1371/journal.pone.0045195.g006
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reported previously [41], we investigated whether the m-opioid
activity of remifentanil could be antagonised by a narcotic
antagonist, naloxone. Preincubation with naloxone attenuated
remifentanil-induced increases in mitochondrial respiration, indi-
cating that the remifentanil effect was mediated by an opioid
receptor mechanism. Furthermore, we observed remifentanil-
induced phosphorylation of IkBa early (within the first 30 min),
denoting the stimulation of NF-kB. Activation of the NF-kB
transcription factor by the m-opioid-receptor agonist and signaling
has been demonstrated [42], and our data again indicate
activation of opioid receptor signaling.
Since it has been shown that anaesthetic drugs might have a
direct effect on isolated mitochondrial oxygen consumption and
bioenergetics [43], we isolated mitochondria from HepG2 cells
and treated them with remifentanil. At the dosage (50 or 500 ng/
ml) used, remifentanil did not interfere with isolated mitochondrial
maximal respiration (state 3) of HepG2 cells, but at 500 ng/ml it
induced an increase in the respiratory control ratio of complex I-
dependent respiration, indicating an increase in respiratory
activity of the isolated mitochondria. Our data are in disagreement
with a study in which the authors observed a reduction in isolated
mitochondrial respiration for mitochondria preincubated with
remifentanil [44]. However, in their study the authors used an
extremely high dose of remifentanil (10,000 to 20,000 ng/ml) in a
different organ (brain) and species (rat).
As mentioned above, remifentanil is an opioid acting on cell
surface m-type receptors [22], and the mechanism through which
remifentanil has a direct effect on isolated mitochondrial
respiration should be investigated in more detail. Remifentanil
might be able to cross the cellular membrane and reach
mitochondria. One can speculate that remifentanil might have a
direct effect on mitochondrial enzymes located in the inner
mitochondrial membranes by interacting with respiratory chain
complexes or may affect proton leakage by binding to the
mitochondrial membrane. While we cannot exclude impaired
function of mitochondria due to the isolation procedure,
maintained quantitative oxygen kinetics using high-resolution
respirometry has been demonstrated [45], and measurements in
isolated mitochondria remain one of the gold standards in studies
addressing mitochondrial physiology.
TNF-a is one of the important mediators of the inflammatory
response seen in sepsis/septic shock and may also induce
mitocondrial dysfunction in human hepatocytes [31]. We inves-
tigated further whether remifentanil interferes with the effects of
TNF-a on mitochondrial respiration. We observed that remifen-
Figure 7. Modulation of the cytokine release. HepG2 superna-
tants’ IL-6 protein content after 24 h of incubation with medium alone
(controls), TNF-a (10 ng/ml) or remifentanil (50 and 500 ng/ml) for 24 h
or preincubation with remifentanil (50 and 500 ng/ml, 1 h incubation)
followed by incubation with TNF-a (10 ng/ml) for an additional 24 h. In
addition, cells were pretreated with naloxone at 1000 ng/ml followed
by incubation with 50 or 500 ng/ml of remifentil or medium alone for
an additional 24 hour (n$3) (C: control, R50: remifentanil 50 ng/ml,
R500: remifentanil 500 ng/ml). Data represent mean6SD. Statistical
analysis for cytokine levels was performed by one-way analysis of
variance (ANOVA): #p= 0.001. Afterwards all groups were divided into
subgroups and subsequent one-way ANOVA was performed in the
subgroups (subgroup 1: control, TNF-a, R50, R500 and naloxone
(p = 0.003); subgroup 2: R50, R500, R50+naloxone, R500+naloxone
p = 0.081; subgroup 3: TNF-a, R50+TNF-a, R500+TNF-a, p = 0.006)
followed by an independent t-test in each subgroup. * = independent
t-test, TNF-a vs. control (p = 0.032). & = independent t-test R500+TNF-a
vs. TNF-a (p = 0.008).
doi:10.1371/journal.pone.0045195.g007
Figure 8. Mitochondrial membrane potential measured by the changes in the 590/530 JC-1 emitted fluorescence. HepG2 cells’
mitochondrial membrane potential after incubation with medium alone for 1 hour (controls, n = 24), remifentanil at 50 (R50, n = 24) or 500 (R500,
n = 32) ng/ml and valinomycin (1 mg/ml, n = 8)). Data represent mean6SD. Statistical analysis was performed using one-way analysis of variance
(ANOVA): # p,0.0001, followed by an independent t-test (*p = 0.002 vs. control, **p = 0.001 vs. control and ***p,0.0001 vs. control).
doi:10.1371/journal.pone.0045195.g008
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Figure 9. HepG2 cells’ mitochondrial ATP. HepG2 cells’ mitochondrial ATP content after incubation with medium alone (controls) or with
remifentanil at 50 (R50) or 500 (R500) ng/mlor for 1 hour. Data represent mean6SD. Statistical analysis was performed using one-way analysis of
variance (ANOVA): # p=0.023, followed by an independent t-test (*p = 0.031 vs. control) (n = 5).
doi:10.1371/journal.pone.0045195.g009
Figure 10. Intact cellular oxygen consumption after incubation with remifentanil. Intact cellular oxygen consumption after incubation
with or without remifentanil at 500 ng/ml for 1 hour. HepG2 cells’ basal oxygen consumption (A), in the presence of oligomycin (B: oligomycin
insensitive respiration), and FCCP (C) (n = 20 each). (C: control [medium alone], R: remifentanil)(n = 20). The uncoupled respiratory control ratio (uRCR)
was calculated as the ratio between the oxygen consumption rate in the presence of FCCP and the rate in the presence of oligomycin (D). Data
represent mean6SD. Statistical significance between samples using paired samples t test is indicated.
doi:10.1371/journal.pone.0045195.g010
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tanil prevented TNF-a-induced mitochondrial dysfunction of
cultured hepatocytes. The regulatory immune functions of m-
opioid receptor activators have also been shown in several animal
models of inflammatory diseases [46,47]. In one study, the opioid
agonist morphine inhibited LPS-induced TNF-a production in
vivo [48]. Chakass et al. showed that m-opioid receptor activation
prevented acute hepatic inflammation and cell death, and the
administration of a selective m-opioid receptor agonist enhanced
hepatoprotective-signaling pathways in vivo [41]. Recently we
showed that pretreatment of cultured hepatocytes with cyclospor-
ine A prevented TNF-a-induced reduction of cellular respiration,
implicating the involvement of the mitochondrial permeability
transition pore openings [31]. Interestingly, in a recent study the
opioid agonist morphine prevented the mitochondrial permeabil-
ity transition pore opening in cardiomyocytes [49]. One can
speculate that remifentanil has the same mode of action as
morphine, by acting on the mitochondrial permeability transition
pore openings.
We further observed anti-apoptotic effects of remifentanil by
attenuating TNF-a-induced fragmentation of pro-caspase-3 into
cleaved active caspase 3. Chakass et al. also showed that treatment
with m-opioid receptor agonist decreased ceramide-induced cell
death in cultured human hepatocytes, indicating an anti-apoptotic
effect of m-opioid receptor agonists [41].
IL-6 plays an important role in innate and acquired immune
responses [50] and is up-regulated during sepsis [51,52]. In
humans, serum levels of IL-6 are increased after TNF-a infusion
[53,54]. Opioids can modulate immune responses, and it has been
reported previously that remifentanil could prevent endotoxin-
induced cytokine release in human whole blood cells in vitro [55].
We therefore exposed the cells under septic conditions, by
incubating with TNF-a to induce IL-6 expression and release in
cellular supernatants, and investigated whether remifentanil could
prevent TNF-a-induced cytokine release. We showed that
remifentanil at a high dose prevented TNF-a-induced Il-6 release.
A limitation of our study is the use of HepG2 cells, which show
certain dissimilarities when compared to cells obtained directly
from patients [56]. For instance, despite similar glucuronide
conjugation compared to human hepatocytes, lower dealkylation
activity and higher microsomal hydrolysis have been reported
[57]. How this may have affected metabolism of the various
compounds used in our study is difficult to judge. Accordingly, the
relevance of our findings for patients should be further investigat-
ed.
In summary, our data show that remifentanil induced an
increase in maximal oxygen consumption of cultured human
hepatocytes which was prevented by preincubation with an opioid
receptor antagonist, indicating that remifentanil’s effect was
mediated by an opioid receptor mechanism. Remifentanil did
not interfere with isolated mitochondrial maximal respiration
(state 3) of HepG2 cells, but it increased the respiratory control
ratio of complex-I-dependent respiration. Preincubation of the
cells with remifentanil prevented TNF-a-induced mitochondrial
dysfunction and attenuated TNF-a-induced fragmentation of pro-
caspase-3 into cleaved active caspase 3 and IL-6 release of HepG2
cells.
The magnitude of the effect of remifentanil on mitochondrial
respiration was small, and is most likely not clinically relevant
under normal conditions. Nevertheless, effects on mitochondrial
respiration of a similar magnitude have been reported for other
commonly used drugs such as nitroglycerin [58], metformin [59]
and various catecholamines [60]. Accordingly, drug-induced
mitochondrial alterations can be potentiated by jointly used drugs
with similar effects. Moreover, patients with mitochondrial
disorders may have a more exaggerated response when exposed
to drugs which normally interfere minimally with mitochondrial
functions.
Materials and Methods
Chemicals and reagents
Remifentanil was obtained from Glaxo-Wellcome AG (Bern,
Switzerland) and naloxone from OrPha Swiss GmbH (Ku¨snacht,
Switzerland). All the reagents for cellular respiration and media for
cell culture, as well as recombinant human TNF-a, polyclonal
anti-actin antibody, and cyclosporin A (CsA), were obtained from
Sigma-Aldrich (Buchs, Switzerland). Caspase-3 antibody was
purchased from Assay Designs (Ann Arbor, MI, USA) and
horseradish peroxidase anti-rabbit secondary antibody from
Abcam (Cambridge, UK).
Cell culture
The human hepatoma cell line HepG2 was cultured in 25 cm2
flasks (for respiration assays) or 24-well plates (for Western blot
analysis) in RPMI 1640 containing 10% heat-inactivated fetal
bovine serum (FBS), 1% non-essential amino acids, 1% glutamine,
1% sodium pyruvate, and 1% penicillin-streptomycin at 37uC in a
humid atmosphere (5% CO2, 95% air), with passage twice a week.
Quiescent cells were obtained by total deprivation of FBS for 14 to
16 hours before the experiments. All experiments were performed
when cells reached 90–95% confluency. Cells were exposed to
remifentanil at 5 or 500 ng/ml for 1 hour, at 50 ng/ml for 1, 2, 4,
8 and 16 hours, or pretreated with naloxone at 1000 ng/ml for
1 hour, followed by incubation with remifentanil at 50 or 500 ng/
ml for an additional hour. In an additional series of experiments,
cells were incubated with TNF-a at 10 ng/ml (200 U/ml) for
1 hour or pretreated with 50 or 500 ng/ml of remifentil, followed
by incubation with TNF-a at 10 ng/ml (200 U/ml) for an
additional hour.
Mitochondrial isolation
Mitochondria were isolated from cultured human hepatocytes
by a method of homogenisation with a Dounce homogeniser (20–
30 strokes), followed by low-speed (600 g) and high-speed
(11,000 g) centrifugations using a Mitochondria Isolation Kit
(Sigma, Switzerland) according to the manufacturer’s instructions.
Cellular respiration (high-resolution respirometry)
After incubation, HepG2 cells were trypsinised and resuspended
in RPMI-1640 with 10% FBS, and then centrifuged for 5 min
(350 g). Cells were resuspended in the respiration buffer [61]
(110 mM sucrose, 0.5 mM EGTA, 3.0 mM MgCl2, 80 mM KCl,
60 mM K-lactobionate, 10 mM KH2PO4, 20 mM taurine,
20 mM hepes, 1.0 g/l BSA, pH 7.1) at a concentration of 1-
26106 cells/ml. Respiration rates were measured at 37uC using a
high-resolution oxygraph (Oxygraph-2k, Oroboros Instruments,
Innsbruck, Austria). Respiration rates were calculated as the time
derivative of oxygen concentration measured in the closed
respirometer and expressed per million viable cells. The amplified
signal was recorded in a computer with online display of the
calibrated oxygen concentration and oxygen flux (DatLab software
for data acquisition and analysis; Oroboros Instruments, In-
nsbruck, Austria). Mitochondrial complex activity was assessed by
a standard titration protocol: first cells were permeabilized with
digitonin (8.1 mM) for 5 min. Afterwards, for complex I-dependent
maximal respiration stimulation, substrates added were glutamate
(10 mM) and malate (5 mM), which provide nicotinamide adenine
dinucleotide (NADH) to the respiratory chain (complex I
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activation), followed by addition of ADP (2.5 mM) (state 3,
maximal respiration). After a stable signal was reached and
marked, rotenone (0.5 mM) was added to inhibit complex I, and
then complex II-dependent respiration was stimulated by adding
succinate (10 mM), which provides flavin adenine dinucleotide
(FADH) to the respiratory chain (complex II activation, state 3).
Afterwards, complex III was inhibited by antimycin A (0.5 mM),
and complex IV-dependent respiration was measured by adding
ascorbate (4 mM) and N,N,N9,N9-tetramethyl-p-phenylendiamine
(TMPD, 0.5 mM). Since TMPD exhibited a wide range of auto-
oxidation in the buffer, respiration was finally inhibited with
sodium azide (5 mM), and the difference between the oxygen
consumption before and after the addition of sodium azide was
interpreted as the real complex IV respiration.
Each individual respiration experiment was performed in two to
four chambers in parallel, one as a control and the others for the
treated cells, and was recorded simultaneously for paired
comparisons of the slopes of the oxygen concentrations of each
individual experiment.
Isolated mitochondrial oxygen consumption
Isolated HepG2 cells’ mitochondria (isolated from 20 to 40
75 cm2 cultured flasks) were incubated with remifentanil at 50 or
500 ng/ml for 1 hour. Isolated mitochondria were resuspended in
the respiration buffer (same buffer used for permeabilized cells) at
a concentration of 0.4 mg/ml, and respiration rates were
measured at 37uC with the high-resolution respirometer. The
medium was equilibrated for 30 to 40 minutes with air in the
oxygraph chambers and stirred at 750 rpm until a stable signal was
obtained for calibration at air saturation. The corresponding
oxygen concentration was calculated from the digitally recorded
barometric pressure and the oxygen solubility at 37uC. The
amplified signal was recorded in a computer with online display of
the calibrated oxygen concentration and oxygen flux (negative
time derivative of oxygen concentration; Dat-Lab software for
data acquisition and analysis; OROBOROS). Oxygen consump-
tion was expressed as pmol/second/mg mitochondrial protein.
Oxygen levels were always maintained above 40 nmol/ml.
Maximal oxidative capacities were determined in the presence of
saturating concentrations of oxygen, ADP (0.25 mmol/l) and
specific mitochondrial substrates. For complex I-dependent
respiration, substrates were glutamate (10 mmol/l) plus malate
(5 mmol/l), which provide nicotinamide adenine dinucleotide
(NADH) to the respiratory chain (complex I activation). For
measurement of complex II-dependent respiration, first complex I
was inhibited with rotenone (0.5 mmol/l), and then succinate
(10 mmol/l) was added, which provides flavin adenine dinucleo-
tide to the respiratory chain (complex II activation). The coupling
of phosphorylation to oxidation was determined by calculating the
respiratory control ratio (RCR) as the ratio between ADP-
stimulated respiration (state 3) and respiration after ADP depletion
(state 4). Complex IV-dependent respiration was measured by
adding ascorbate (4 mM) and N,N,N9,N9-tetramethyl-p-pheny-
lendiamine (TMPD, 0.5 mM). Since TMPD exhibited a wide
range of auto-oxidation in the buffer, respiration was finally
inhibited with sodium azide (5 mM), and the difference between
the oxygen consumption before and after the addition of sodium
azide was interpreted as the real complex IV (state 3) respiration.
Measurement of phosphorylation of IkBa
To demonstrate that the remifentanil effect was mediated by a
cell surface opioid receptor, we measured phosphorylation and
activation of IkBa. Detection and analysis of IkBa phosphoryla-
tion of cell extract of remifentanil-induced (50 and 500 ng/ml, for
30 min) HepG2 were performed with a FunctionELISATM IkBa
assay kit (Active Motif, Carlsbad, CA, USA) according to the
manufacturer’s instructions.
Sodium dodecyl sulphate polyacrylamide gel
electrophoresis (SDS-PAGE) and Western blotting
SDS-PAGE and immunoblot analysis were performed as
described previously [31]. Briefly, for immunoblot analysis of
caspase 3, quiescent cells (cultured in 24-well plates) obtained by
total deprivation of FBS for 14 to 16 hours before the experiments,
were incubated with TNF-a at 10 ng/ml (200 U/ml) for 24 hours
or pretreated with 50 or 500 ng/ml of remifentil for 1 hour,
followed by incubation with medium alone or TNF-a at 10 ng/ml
(200 U/ml) for an additional 24 hours. Afterwards, the cells were
lysed in 60 mM Tris-HCl, 8.5% glycerol, and 2% SDS. The
protein concentration was determined with the Quant-iTM assay
kit and read with the Qubit-TM fluorometer (InvitrogenH, Basel,
Switzerland). Equal amounts of protein (20 mg per line) were
loaded and separated by 4–12% SDS-PAGE. Gels were then
transferred into nitrocellulose membranes with the iBlot-TM dry
blotting system (InvitrogenH, Basel, Switzerland). Equal loading
was verified by staining the exgel with Simply Blue-TM SafeStain
(InvitrogenH, Basel, Switzerland). Afterwards, the membranes
were blocked for 30 min with the incubation buffer (10 mM Tris-
HCl pH 7.5, 100 mM NaCl and 0.1% W/V Tween 20)
supplemented with 5% non-fat dry skim milk, and then incubated
overnight with the primary antibodies: polyclonal caspase-3
antibody (dilution 1:1000; the antibody recognizes both the
precursor procaspase-3 ,36 kDa and the mature active enzymes
of 17–20 kDa following cleavage by upstream caspases) and anti-
actin antibody (dilution 1:3000). The membranes were then
washed three times with incubation buffer and incubated for
1 hour with horseradish peroxidase goat polyclonal anti-rabbit
IgG (dilution 1:3000). Afterwards, membranes were developed
with the enhanced chemiluminescence detection kit (Pierce,
Rockford, IL, USA). Cleaved caspase-3 protein levels (bands)
were analyzed and quantified densimetrically by using Quantity
One software from Bio-Rad. The relative levels of cleaved caspase
3 expression were normalized to actin, and the results are
expressed as arbitrary units (means+/2SD). All Western blotting
experiments were performed in quintuplicate.
Enzyme-linked immunosorbent assay (ELISA)
To investigate whether incubation with TNF-a induced the
expected pro-inflammatory (IL-6) and anti-inflamatory (IL-10)
cytokine release, and whether this effect could also be prevented
by remifentanil, IL-6 and IL-10 contents in cell supernatants were
measured using the LEGEND MAXTM Human ELISA Kit
(Biolegend, San Diego, CA, USA) according to the manufacturer’s
instructions. For ELISA, cells were incubated with TNF-a at
10 ng/ml (200 U/ml) for 24 hours or pretreated with 50 or
500 ng/ml of remifentil, followed by incubation with medium
alone or TNF-a at 10 ng/ml (200 U/ml) for an additional
24 hours. In addition, cells were also pretreated with naloxone at
1000 ng/ml, followed by incubation with 50 or 500 ng/ml of
remifentil or medium alone for an additional 24 hours.
Measurement of mitochondrial membrane potential in
intact cells
The mitochondrial electrochemical potential gradient (Dym) in
intact cells was measured using the cationic dye JC-1 (5,59,69,69-
tetrachloro-1,19,3,39-tetraethylbenzimidazolocarbocyanine io-
dide). JC-1 is a mitochondrial sensor which aggregates in polarized
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mitochondria, where it forms red fluorescent aggregates (J-
aggregates). Dissipation of the mitochondrial membrane potential
prevents the accumulation of the JC-1 dye in the mitochondria,
and the dye is dispersed throughout the entire cell, leading to a
shift from red (J-aggregates) to green fluorescence (JC-1 mono-
mers). Thus the loss of JC-1 aggregates directly correlates with
changes in Dym. Briefly, for these experiments, the cells were
grown in 96-well plates and treated with remifentanil for 1 hour
(50 and 500 ng/ml), and the mitochondrial membrane potential
was measured using the JC-1 mitochondria staining kit for
mitochondrial potential change detection (Sigma, Switzerland)
according to the manufacturer’s instructions. Cells serving as
positive controls were treated with valinomycin (1 mg/ml, for
1 hour), which dissipates the mitochondrial electrochemical
potential. Dym was measured immediately by fluormetry. For
JC-1 monomers, the fluorimeter was set at a 490 nm excitation
wavelength and 530 nm emission wavelength and fluorescence
was measured. For JC-1 aggregates, the fluorimeter was set at a
525 nm excitation wavelength and 590 nm emission wavelength
and fluorescence was measured. Afterwards, the Dym (590/
530 nm fluorescence ratio) was calculated.
Measurement of the HepG2 cells ATP content
Detection and analysis of total cellular ATP content of
remifentanil-treated (50 and 500 ng/ml, for 1 hour) HepG2 cells
were performed using the ATP determination kit (InvitrogenH,
Basel, Switzerland) according to the manufacturer’s instructions.
Coupled and uncoupled respiration of intact cells
After incubation with remifentanil (500 ng/ml, 1 hour), HepG2
cells were trypsinised and resuspended in RPMI-1640 with 10%
FBS, and then centrifuged for 5 min (350 g). Cells were
resuspended in the respiration buffer (110 mM sucrose, 0.5 mM
EGTA, 3.0 mM MgCl2, 80 mM KCl, 60 mM K-lactobionate,
10 mM KH2PO4, 20 mM taurine, 20 mM hepes, 1.0 g/l BSA,
pH 7.1) at a concentration of 1- 26106 cells/ml. Respiration rates
were measured at 37uC using a high-resolution oxygraph
(Oxygraph-2k, Oroboros Instruments, Innsbruck, Austria). Basal
coupled endogenous respiration of intact cells (oxygen consump-
tion without the addition of exogenous substrate) was measured
and recorded using the linear rate of oxygen consumption.
Afterwards, oligomycin (an inhibitor of ATP synthase) (0.4 mg/ml)
was added and the non-phosphorylating respiration rate was
measured (oligomycin-insensitive respiration). Afterwards the
chemical uncoupler FCCP (carbonyl cyanide p-trifluoromethoxyphenylhy-
drazone) was sequentially added at different concentrations (0.1 to
0.8 mM) and maximal uncoupled respiration was recorded. The
uncoupled respiratory control ratio (uRCR) was calculated as the
ratio between the oxygen consumption rate in the presence of
FCCP and the rate in the presence of oligomycin. The oligomycin-
sensitive respiration (ATP turnover) was calculated by subtracting
the oligomycin-insensitive respiration from basal endogenous
respiration.
Statistics
The SPSS 15.0 software package (SPSS IncH, Chicago, IL,
USA) was used for statistical analysis. Comparisons of the slopes of
the oxygen concentrations (cellular respiration) of each individual
experiment were made using the paired samples t test. Unpaired
Student’s t tests were performed for evaluation of significance of
phosphorylation of IkBa. Statistical analysis of cytokine levels (log-
transformed values to normalize the data distribution) and
densitometric analysis of cleaved caspase protein levels were
performed by one-way analysis of variance (ANOVA). Afterwards
the groups were divided into subgroups and subsequent one-way
ANOVA was performed in the subgroups (for cytokines: subgroup
1: control, TNF-a, remifentanil 50 ng/ml [R50], remifentanil
500 ng/ml [R500], and naloxone; subgroup 2: remifentanil
50 ng/ml [R50], remifentanil 500 ng/ml [R500], remifentanil
50 ng/ml [R50]+naloxone, remifentanil 500 ng/ml [R500]+nal-
oxone; subgroup 3: TNF-a, remifentanil 50 ng/ml [R50]+TNF-a,
remifentanil 500 ng/ml [R500]+TNF-a, and for densitometric
analysis of cleaved caspase: subgroup 1: control, TNF-a,
remifentanil 50 ng/ml [R50] and remifentanil 500 ng/ml
[R500], and subgroup 2: TNF-a, remifentanil 50 ng/ml
[R50]+TNF-a and remifentanil 500 ng/ml [R500]+TNF-a)
followed by an independent t-test. All data are presented as
mean6SD, and a p,0.05 was considered significant.
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